Surrozen, Inc./DE (SRZNW)
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
Address
171 OYSTER POINT BLVD
SOUTH SAN FRANCISCO, CA 94080
Founded
2015
Number of Employees
42
Website
http://www.surrozen.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | $2,677 | $15 | - | $1,346 |
| Average Price | - | - | - | - | - | - | - | - | $6.00 | $118.73 | - | $6.03 |
| # Shares Purchased | - | - | - | - | - | - | - | - | 446,200 | 131 | - | 223,165 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | 33.3% | -93.3% | - | 32.6% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | 37.3% | 31.3% | - | 34.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | -3.9% | -124.6% | - | -1.7% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | 72% | 0% | - | 63% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at SRZNW make a trade.
Creating a free account takes less than one minute